Chronic Liver Disease (CLD)

A 56-year-old man with a history of long-term alcohol use presents with progressive abdominal distension, lower-limb edema, fatigue, and confusion. Physical examination reveals jaundice, spider angiomas, ascites with shifting dullness, and asterixis. Laboratory investigations show elevated bilirubin, prolonged INR, low albumin, and thrombocytopenia. Ultrasound demonstrates a nodular liver with splenomegaly and ascites. Diagnosis?

Diagnosis is Decompensated Cirrhosis, most likely due to Alcohol-Associated Liver Disease.

This patient has portal hypertension, ascites, impaired hepatic function, and probable overt hepatic encephalopathy, indicating hepatic decompensation.

1. Definition

Cirrhosis is an advanced stage of chronic liver disease characterized by:

1.      Diffuse hepatic fibrosis

2.      Regenerative nodules

3.      Distortion of normal hepatic architecture

4.      Development of portal hypertension and hepatic dysfunction

Fibrosis may partially regress when the underlying cause is successfully treated, but clinically significant portal hypertension and its complications may persist.

2. Etiology

2.1 Common Causes

1.      Alcohol-associated liver disease

2.      Metabolic dysfunction-associated steatotic liver disease, including MASH

3.      Chronic hepatitis B

4.      Chronic hepatitis C

In this patient, long-term alcohol use makes alcohol-associated cirrhosis the most likely etiology, although coexisting causes should be excluded when appropriate.

2.2 Other Causes

1.      Autoimmune hepatitis

2.      Hereditary hemochromatosis

3.      Wilson disease

4.      Alpha-1 antitrypsin deficiency

5.      Primary biliary cholangitis

6.      Primary sclerosing cholangitis

7.      Budd-Chiari syndrome

3. Pathophysiology

1.      Chronic hepatic injury activates hepatic stellate cells

2.      Collagen and extracellular matrix deposition cause progressive fibrosis

3.      Fibrosis and regenerative nodules distort hepatic architecture

4.      Increased intrahepatic resistance produces portal hypertension

5.      Splanchnic vasodilation and neurohormonal activation cause sodium and water retention

6.      Progressive hepatocellular dysfunction impairs synthetic and metabolic function

7.      Portosystemic shunting and impaired ammonia handling contribute to hepatic encephalopathy

4. Compensated vs Decompensated Cirrhosis

4.1 Compensated Cirrhosis

1.      No previous major decompensating event

2.      May be asymptomatic

3.      Aminotransferases may be normal or mildly elevated

4.      Clinically significant portal hypertension may already be present

4.2 Decompensated Cirrhosis

Major first decompensating events include:

1.      Clinically evident ascites or hepatic hydrothorax

2.      Variceal bleeding

3.      Overt hepatic encephalopathy, West Haven grade II or higher

Jaundice may accompany advanced decompensation but is not, by itself, a universally accepted defining first decompensating event.

Important complications include:

1.      Spontaneous bacterial peritonitis

2.      Hepatorenal syndrome

3.      Recurrent variceal bleeding

4.      Progressive liver failure

A first major decompensating event should prompt hepatology assessment and consideration of liver transplantation.

5. Clinical Features

5.1 Portal Hypertension

1.      Ascites

2.      Splenomegaly

3.      Gastroesophageal varices

4.      Portal hypertensive gastropathy

5.      Thrombocytopenia

Thrombocytopenia commonly results from splenic sequestration and reduced hepatic thrombopoietin production.

5.2 Chronic Liver Disease Stigmata

1.      Jaundice

2.      Spider angiomas

3.      Palmar erythema

4.      Gynecomastia

5.      Testicular atrophy

6.      Muscle wasting and sarcopenia

5.3 Hepatic Encephalopathy

Hepatic encephalopathy is a clinical diagnosis.

Features include:

1.      Sleep-wake disturbance

2.      Cognitive or personality changes

3.      Confusion

4.      Asterixis

5.      Somnolence

6.      Coma in severe disease

This patient's confusion and asterixis strongly support probable overt hepatic encephalopathy, but other causes of altered mental status should be excluded, including:

1.      Infection

2.      Intracranial pathology

3.      Alcohol withdrawal

4.      Wernicke encephalopathy

5.      Medications or sedatives

6.      Hypoglycemia

7.      Electrolyte disturbances

6. Diagnosis

Diagnosis is based on the combination of:

1.      Clinical findings

2.      Laboratory abnormalities

3.      Imaging

4.      Noninvasive assessment when needed

6.1 Laboratory Findings

Common abnormalities include:

1.      Elevated bilirubin

2.      Low albumin

3.      Prolonged INR

4.      Thrombocytopenia

5.      Hyponatremia in advanced disease

6.      Renal dysfunction

AST and ALT may be normal or only mildly elevated in advanced cirrhosis.

Albumin and INR reflect aspects of hepatic synthetic function, but both are influenced by factors outside the liver.

INR in cirrhosis does not accurately predict bleeding risk.

6.2 Etiologic Evaluation

When appropriate, evaluate for:

1.      Hepatitis B and C

2.      Metabolic risk factors for MASLD

3.      Autoimmune hepatitis

4.      Hemochromatosis

5.      Wilson disease

6.      Alpha-1 antitrypsin deficiency

7.      Cholestatic liver disease

Laboratory patterns such as AST greater than ALT, macrocytosis, or elevated GGT may support alcohol-associated liver disease but are not diagnostic.

7. Imaging

7.1 Abdominal Ultrasound With Doppler

May demonstrate:

1.      Nodular liver

2.      Splenomegaly

3.      Ascites

4.      Portosystemic collaterals

5.      Portal or hepatic vein thrombosis

6.      Abnormal portal venous flow

In this patient, a nodular liver with splenomegaly and ascites strongly supports cirrhosis with portal hypertension.

7.2 Transient Elastography

Useful for noninvasive assessment of liver stiffness, particularly earlier in chronic liver disease.

7.3 Liver Biopsy

Usually not required when cirrhosis is clinically and radiologically established.

Biopsy may be considered when the diagnosis or etiology remains uncertain. A transjugular approach may be preferred when significant ascites or bleeding concerns are present.

8. Major Complications

8.1 Ascites

Diagnosis

Diagnostic paracentesis should be performed in:

1.      New-onset ascites

2.      Patients with cirrhosis and ascites admitted emergently to the hospital

3.      Patients with ascites who develop fever, abdominal pain, encephalopathy, hypotension, GI bleeding, or renal deterioration

Initial fluid studies include:

1.      Cell count and differential

2.      Ascitic albumin

3.      Total protein

4.      Ascitic fluid culture in emergently hospitalized patients, preferably by bedside inoculation into aerobic and anaerobic blood-culture bottles

For uncomplicated new outpatient ascites without concern for infection, routine culture is not always necessary.

SAAG ≥1.1 g/dL strongly supports portal hypertension.

Routine correction of elevated INR or thrombocytopenia before uncomplicated paracentesis is generally not required.

Treatment

1.      Sodium restriction, approximately 2 g/day

2.      Spironolactone with or without furosemide

3.      A common combination is spironolactone 100 mg plus furosemide 40 mg daily

4.      Large-volume paracentesis for tense or refractory ascites

5.      If >5 L is removed, give albumin approximately 6 to 8 g per liter removed

6.      Consider TIPS for appropriately selected patients with refractory ascites

Routine fluid restriction is unnecessary unless significant hyponatremia is present.

Avoid NSAIDs. ACE inhibitors and ARBs are generally avoided in patients with cirrhosis and ascites because of the risk of hypotension and renal dysfunction.

8.2 Spontaneous Bacterial Peritonitis

Diagnosis

Ascitic PMN ≥250 cells/µL warrants treatment for SBP.

Do not delay treatment while awaiting culture results.

Treatment

1.      Third-generation cephalosporin, such as cefotaxime or ceftriaxone, for many community-acquired cases

2.      Broader treatment when healthcare-associated infection or multidrug-resistant organisms are likely

3.      IV albumin using the standard regimen:

o    1.5 g/kg on day 1

o    1 g/kg on day 3

Albumin provides greatest benefit in patients with renal dysfunction or severe hepatic dysfunction.

Secondary antibiotic prophylaxis is generally indicated after an episode of SBP. Primary prophylaxis is reserved for selected high-risk patients.

8.3 Esophageal Varices and Acute Variceal Hemorrhage

Primary Prevention

In patients with cirrhosis and varices who require primary prophylaxis:

1.      Use a nonselective beta blocker, such as carvedilol, propranolol, or nadolol, when appropriate

2.      Carvedilol is preferred in suitable patients because of its greater portal-pressure reduction

3.      Endoscopic variceal ligation is an alternative when nonselective beta blockers are contraindicated or not tolerated

4.      In patients with ascites, reduce or discontinue the nonselective beta blocker if:

o    SBP remains <90 mm Hg

o    MAP remains <65 mm Hg

o    HRS-AKI develops

5.      The nonselective beta blocker may be restarted and retitrated after blood pressure recovers or HRS-AKI resolves

Acute Variceal Hemorrhage

1.      Stabilize airway and circulation

2.      Use a restrictive transfusion strategy, generally initiating red-cell transfusion around Hb 7 g/dL and targeting approximately 7 to 8 g/dL

3.      Individualize transfusion according to ongoing bleeding, cardiovascular disease, age, and hemodynamic status

4.      Start octreotide, terlipressin, or somatostatin immediately

5.      Start antibiotic prophylaxis, commonly ceftriaxone

6.      Perform upper endoscopy within approximately 12 hours after appropriate stabilization

7.      Perform endoscopic variceal ligation for bleeding esophageal varices

8.      Continue vasoactive therapy for approximately 2 to 5 days

Consider preemptive TIPS within 72 hours, ideally within 24 hours, in selected high-risk patients, including:

1.      Child-Pugh C with score 10 to 13

2.      Child-Pugh B with score >7 and active bleeding at endoscopy

Secondary Prevention

Following recovery from esophageal variceal bleeding:

1.      Carvedilol or another nonselective beta blocker plus repeated endoscopic variceal ligation

2.      Carvedilol is preferred when tolerated

3.      Consider TIPS when standard secondary prophylaxis fails or is not feasible

8.4 Hepatic Encephalopathy

Common precipitants include:

1.      Infection

2.      Gastrointestinal bleeding

3.      Constipation

4.      Dehydration or overdiuresis

5.      Hypokalemia

6.      Renal dysfunction

7.      Sedative medications

Treatment

1.      Identify and treat the precipitating factor

2.      Lactulose is first-line therapy

3.      Titrate lactulose to approximately 2 to 3 soft stools daily

4.      Add rifaximin to lactulose for prevention of recurrent overt hepatic encephalopathy, particularly after the second episode

Serum ammonia correlates poorly with clinical severity and should not be used alone to diagnose or grade hepatic encephalopathy.

A normal ammonia level in a patient suspected of having overt hepatic encephalopathy should prompt reconsideration of the diagnosis.

8.5 Hepatorenal Syndrome With Acute Kidney Injury

Current HRS-AKI criteria include:

1.      Cirrhosis with ascites

2.      Increase in creatinine ≥0.3 mg/dL within 48 hours or ≥50% from baseline within 7 days, and/or urine output ≤0.5 mL/kg/h for ≥6 hours

3.      No improvement within approximately 24 hours after adequate volume resuscitation when clinically indicated

4.      No strong evidence for another primary cause of AKI

A routine 48-hour albumin challenge is no longer required to diagnose HRS-AKI.

Treatment

1.      Treat precipitating factors

2.      Stop nephrotoxic or hemodynamically harmful medications when appropriate

3.      Terlipressin plus albumin is preferred where available and appropriate

4.      Norepinephrine is an effective alternative, generally in an ICU setting

5.      Monitor carefully for volume overload and respiratory complications

6.      Liver transplantation is the definitive treatment in suitable candidates

9. Hepatocellular Carcinoma

Surveillance

For patients with cirrhosis who remain candidates for HCC-directed treatment:

1.      Liver ultrasound plus AFP

2.      Every 6 months

AFP alone is insufficient.

Routine surveillance is generally not recommended in patients with Child-Pugh C cirrhosis who are not transplant candidates.

Diagnosis

Suspicious lesions are evaluated using:

1.      Multiphasic CT

2.      Contrast-enhanced MRI

Characteristic imaging in an appropriate at-risk patient may establish HCC without biopsy.

10. Severity Assessment

10.1 Child-Pugh Score

Includes:

1.      Bilirubin

2.      Albumin

3.      INR or PT

4.      Ascites

5.      Hepatic encephalopathy

Classification:

1.      Class A: 5 to 6

2.      Class B: 7 to 9

3.      Class C: 10 to 15

Child-Pugh class should not be equated directly with compensated versus decompensated cirrhosis.

10.2 MELD 3.0

For adults, MELD 3.0 incorporates:

1.      Bilirubin

2.      INR

3.      Creatinine

4.      Sodium

5.      Albumin

6.      Female sex

The equation also contains interaction terms.

MELD 3.0 is used for short-term mortality assessment and transplant prioritization in applicable systems.

Age is not itself a variable in the adult MELD 3.0 equation.

A fixed MELD threshold should not be the sole trigger for transplant referral.

11. General Management

1.      Treat the underlying cause

2.      Recommend complete alcohol abstinence

3.      Provide evidence-based treatment for alcohol use disorder

4.      Refer for hepatology and transplant assessment when appropriate

5.      Vaccinate against HAV and HBV if nonimmune, influenza, pneumococcus, COVID-19, and other age-appropriate infections

6.      Maintain protein intake of approximately 1.2 to 1.5 g/kg ideal body weight/day

7.      Do not routinely restrict protein, including in hepatic encephalopathy

8.      Minimize prolonged fasting and consider a late-evening snack

9.      Avoid NSAIDs and unnecessary sedatives

10.  Avoid nephrotoxins when possible

11.  Screen for malnutrition, frailty, and sarcopenia

Acetaminophen is generally preferred to NSAIDs when analgesia is required and is commonly limited to approximately 2 g/day, with additional caution in ongoing heavy alcohol use or malnutrition.

12. Liver Transplantation

Patients with decompensated cirrhosis should be considered for liver transplantation.

Consider transplant evaluation after:

1.      First or recurrent hepatic decompensation

2.      Clinically significant or refractory ascites

3.      Variceal hemorrhage

4.      Recurrent hepatic encephalopathy

5.      HRS-AKI

6.      Progressive jaundice or hepatic dysfunction

7.      Increasing MELD score

8.      HCC meeting transplant criteria

9.      Other qualifying complications such as hepatopulmonary syndrome

A MELD score around 15 has historically been associated with increasing survival benefit from transplantation, but clinical decompensation itself is an important indication for early evaluation.

13. Key Clinical Insight

Ascites + portal hypertension + impaired hepatic function + probable overt hepatic encephalopathy strongly indicate decompensated cirrhosis.

In this patient:

Long-term alcohol use + nodular liver + splenomegaly + ascites + jaundice + thrombocytopenia + low albumin + prolonged INR + confusion and asterixis = decompensated cirrhosis, most likely due to alcohol-associated liver disease, with portal hypertension and probable overt hepatic encephalopathy.

References

1.      Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884.

2.      Baveno VIII Faculty. Baveno VIII: Advancing Consensus in Portal Hypertension. Journal of Hepatology. 2026. doi:10.1016/j.jhep.2026.07.030.

3.      Nadim MK, Kellum JA, Forni LG, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative and International Club of Ascites joint multidisciplinary consensus meeting. Journal of Hepatology. 2024;81(1):163-183. doi:10.1016/j.jhep.2024.03.031.